54 research outputs found
Interface conditions for fast-reaction fronts in wet porous mineral materials: the case of concrete carbonation
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study
© 2022 The Authors. Published by Taylor & Francis. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1080/16078454.2022.2082725Objectives
There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination with pomalidomide and dexamethasone (IsaPomDex). In this UK-wide retrospective study, we set out to evaluate infections experienced by routine care patients who received this novel therapy across 24 cancer centres during the COVID-19 pandemic.
Methods
The primary endpoint was infection morbidity (incidence, grading, hospitalization) as well as infection-related deaths. Secondary outcomes were clinical predictors of increased incidence of any grade (G2–5) and high grade (≥G3) infections.
Results
In a total cohort of 107 patients who received a median (IQR) of 4 cycles (2–8), 23.4% of patients experienced ≥1 any grade (G2–5) infections (total of 31 episodes) and 18.7% of patients experienced ≥1 high grade (≥G3) infections (total of 22 episodes). Median time (IQR) from start of therapy to first episode was 29 days (16–75). Six patients experienced COVID-19 infection, of whom 5 were not vaccinated and 1 was fully vaccinated. The cumulative duration of infection-related hospitalizations was 159 days. The multivariate (MVA) Poisson Regression analysis demonstrated that a higher co-morbidity burden with Charlson Co-morbidity Index (CCI) score ≥4 (incidence rate ratio (IRR) = 3, p = 0.012) and sub-optimal myeloma response less than a partial response (<PR) (p = 0.048) are independent predictors of ≥ G3 infections.
Conclusion
Our study described initial results of infection burden during IsaPomDex treatment. We recommend close monitoring particularly in elderly patients with co-morbidities, the effective use of an-infective prophylaxis, as well as optimal vaccination strategies, to limit infections
Dynamics of an explosion bubble close to a structure
SIGLEAvailable from British Library Document Supply Centre-DSC:DXN037116 / BLDSC - British Library Document Supply CentreGBUnited Kingdo
Imperforate hymen: Retrospective review from a single tertiary centre of presenting symptoms and diagnostic process
Recommended from our members
The effect of a retarder on the early stages of cement hydration
Predominance of Chlamydia trachomatis Serovars Associated with Urogenital Infections in Females in New Delhi, India
Screening for Chlamydia trachomatis was done for 280 endocervical swab samples by PCR specific for endogenous plasmid. Age dependency was seen in symptomatic patients, with a high chlamydial prevalence rate (28%) found in younger women. Genotyping by restriction fragment length polymorphism analysis of omp1 PCR-positive samples showed serovars D, E, and F to be the most prevalent
Pleural effusion as an initial manifestation in a patient with primary pulmonary monoclonal B-cell lymphocyte proliferative disease
Prediction of Quantitative Intrathoracic Fluid Volume To Diagnose Pulmonary Edema Using Labview, Computer Methods in Biomechanics and Biomedical Engineering
Pulmonary oedema is a life-threatening disease that requires special attention in the area of research and clinical diagnosis.
Computer-based techniques are rarely used to quantify the intrathoracic fluid volume (IFV) for diagnostic purposes. This
paper discusses a software program developed to detect and diagnose pulmonary oedema using LabVIEW. The software
runs on anthropometric dimensions and physiological parameters, mainly transthoracic electrical impedance (TEI). This
technique is accurate and faster than existing manual techniques. The LabVIEW software was used to compute the
parameters required to quantify IFV. An equation relating per cent control and IFV was obtained. The results of predicted
TEI and measured TEI were compared with previously reported data to validate the developed program. It was found that
the predicted values of TEI obtained from the computer-based technique were much closer to the measured values of TEI.
Six new subjects were enrolled to measure and predict transthoracic impedance and hence to quantify IFV. A similar
difference was also observed in the measured and predicted values of TEI for the new subjects
- …